Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
'Cost saving' was suggested in our recent economic evaluation of chemoprevention of breast cancer targeting women at high risk in Japan. However, this budget impact analysis reveals that the introduction of chemoprevention appears to be not budget saving for approximately 20 years, whereas the level of budget impact seems affordable.
Kondo
Masahide
M
Department of Health Care Policy and Management, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8577, Japan. mkondo@md.tsukuba.ac.jp
Hoshi
Shu-Ling
SL
Toi
Masakazu
M
D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000191:economics* / Q000517:prevention & control*; D018890:Chemoprevention / Q000191:economics / Q000379:methods; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D020847:Estrogen Receptor Modulators / Q000191:economics / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D007564:Japan; D008875:Middle Aged; D011322:Primary Prevention / Q000191:economics / Q000379:methods; D020849:Raloxifene Hydrochloride / Q000191:economics / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D013629:Tamoxifen / Q000191:economics / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride